Adalimumab‐induced platelet antibodies resulting in severe thrombocytopenia

A 73‐year‐old male with Crohn's disease on adalimumab developed deep thrombocytopenia (platelets 24x109/L), cutaneous hematomas and mild epistaxis. Platelet count normalised after adalimumab discontinuation. Authors recommend monitoring platelets after initiating anti‐TNFα agents

Source:

British Journal of Clinical Pharmacology